Co-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich, Germany

Rhea-AI Summary

Co-Diagnostics (NASDAQ:CODX) will present at ESCMID Global 2026, April 17-21 in Munich, Germany, showcasing its CE-IVD testing solutions and the upcoming Co-Dx PCR platform.

Company representatives will meet global customers and distributors at Booth #G55. The Co-Dx PCR platform is under regulatory review and not yet for sale.

News Market Reaction – CODX

-4.83%

2 alerts

-4.83% Session close to close

+4.4% Peak Tracked

$5.22M Market Cap

0.0x Rel. Volume

In the Apr 14 session, CODX declined 4.83%, reflecting a moderate negative market reaction. Argus tracked a peak move of +4.4% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement emphasizes CODX’s participation at ESCMID Global 2026, using the conference’s more...

Analysis

This announcement emphasizes CODX’s participation at ESCMID Global 2026, using the conference’s more than 16,000 registrants to showcase its CE-IVD test menu and upcoming Co-Dx PCR platform. In recent months, the company has paired global expansion and joint ventures with weak 2025 financial results and going-concern language in its 10-K. Investors may watch execution on regulatory clearances, commercialization milestones, and cash runway developments as the platform advances from visibility to potential revenue generation.

Key Figures

ESCMID Global registrants: more than 16,000 registrants Conference dates: April 17–21, 2026

2 metrics

ESCMID Global registrants more than 16,000 registrants Historical attendance at ESCMID Global events

Conference dates April 17–21, 2026 Dates of ESCMID Global 2026 in Munich

Historical Context

5 past events · Latest: Apr 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 09	Trade mission update	Positive	+3.6%	Executives joining European trade mission to build partnerships and support PCR platform.
Apr 02	JV facility approval	Positive	-4.9%	Saudi industrial land allocation for CoMira manufacturing facility supporting local diagnostics production.
Mar 31	Earnings results	Negative	-12.9%	Full-year 2025 results with steep revenue decline and large net loss and impairment.
Mar 25	Clinical studies update	Positive	-13.2%	Shipment of instruments and TB test kits to India for WHO-guided clinical performance studies.
Mar 20	Territory expansion	Positive	-2.3%	CoSara commercial territory expansion across South Asia to a larger diagnostics addressable market.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Commercial and strategic updates often saw weak or negative price reactions, while clearly negative financials aligned with downside.

Recent Company History

Over the past month, Co-Diagnostics has reported sharply lower 2025 revenue of $0.6M and a $46.9M net loss, alongside going-concern language in its filings. At the same time, it has expanded its South Asia territory to an estimated $13.0B market, advanced TB clinical studies in India, and moved forward with the CoMira facility in Saudi Arabia. A European trade mission and presence at ESCMID Global 2026 fit this push for international commercialization and broader distribution of its PCR platforms.

Key Terms

molecular diagnostics, pcr, ce-ivd, fda

4 terms

molecular diagnostics medical

"a molecular diagnostics company with a unique, patented platform"

Molecular diagnostics are laboratory tests that look for specific molecules — such as genes, pieces of DNA or RNA, or proteins — to detect disease, predict risk, or guide treatment choices. For investors, these tests matter because they can change how illnesses are diagnosed and treated, create recurring revenue through specialized tests and companion products, and face clear regulatory and reimbursement pathways that drive commercial value; think of them as reading a biological barcode to inform medical decisions.

pcr medical

"the upcoming Co-Dx PCR platform*"

PCR (polymerase chain reaction) is a laboratory method that makes many copies of a tiny piece of genetic material (DNA or RNA) so scientists can detect and study it reliably — think of photocopying a faint, tiny note until the words are easy to read. For investors, PCR matters because it underpins diagnostic tests, drug development, and biotech tools whose sales, regulatory approvals, and real-world use can materially affect company revenues and market perceptions during health events or product launches.

ce-ivd regulatory

"showcasing the Company's suite of CE-IVD testing solutions for clinical laboratories"

CE‑IVD is the European conformity mark showing that an in vitro diagnostic device — a medical test used on samples like blood or tissue — meets the EU’s safety and performance requirements for sale. For investors, it’s like a stamped passport that opens access to EU markets, signaling lower regulatory risk, broader commercial potential, and a clearer path to revenue for companies that make diagnostic tests.

fda regulatory

"subject to review by the FDA and/or other regulatory bodies"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to engage with global customers and distributors while expanding international commercial relationships

SALT LAKE CITY, April 14, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will participate in the Congress of the European Society of Clinical Microbiology and Infectious Disease ("ESCMID Global") 2026, taking place April 17-21 in Munich, Germany.

ESCMID Global 2026 features academic and industry programming that brings together clinical microbiology and infectious diseases leaders dedicated to advancing scientific, education, research and state-of-the-art technologies. Prior ESCMID Global events have historically attracted more than 16,000 registrants, nearly a third of which originated from outside of Europe, underscoring its role as the premier global forum for the infectious disease community.

Company representatives look forward to establishing and strengthening relationships with new and existing customers and distributors from around the world while also showcasing the Company's suite of CE-IVD testing solutions for clinical laboratories, as well as the upcoming Co-Dx PCR platform*.

Registrants interested in learning more about Co-Diagnostics are invited to visit Booth #G55.     

*The Co-Dx PCR platform (including the PCR Home^®, PCR Pro^®, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-to-showcase-co-dx-pcr-platform-and-ce-ivd-solutions-at-escmid-2026-in-munich-germany-302741220.html

SOURCE Co-Diagnostics

FAQ

When will Co-Diagnostics (CODX) present at ESCMID Global 2026 in Munich?

Co-Diagnostics will participate April 17-21, 2026 at ESCMID Global in Munich. According to Co-Diagnostics, company staff will engage global customers and distributors at Booth #G55 to showcase CE-IVD testing solutions and the Co-Dx PCR platform.

What will Co-Diagnostics (CODX) showcase at ESCMID Global 2026?

Co-Diagnostics will showcase its CE-IVD testing solutions and the upcoming Co-Dx PCR platform. According to Co-Diagnostics, demonstrations include the suite of CE-IVD tests and information about PCR Home, PCR Pro, and companion mobile app.

Is the Co-Dx PCR platform available for sale at ESCMID Global 2026 (CODX)?

No, the Co-Dx PCR platform is not yet for sale and remains under regulatory review. According to Co-Diagnostics, the platform and associated tests are subject to FDA and other regulatory reviews before commercial availability.

Where can attendees find Co-Diagnostics (CODX) at ESCMID Global 2026?

Attendees can visit Co-Diagnostics at Booth #G55 during the April 17-21 event in Munich. According to Co-Diagnostics, company representatives will be available to discuss CE-IVD products and international distribution opportunities.

How will Co-Diagnostics (CODX) use ESCMID Global 2026 to expand internationally?

Co-Diagnostics aims to establish and strengthen distributor and customer relationships at the Congress. According to Co-Diagnostics, engagement with registrants from over 16,000 past attendees will support international commercial development and product awareness.